Evolution of symptoms and quality of life during Zika virus infection: A 1-year prospective cohort study

Laval, Franck de; d’Aubigny, Hubert; Matheus, Séverine; Labrousse, Thomas; Ensargueix, Anne Laure; Lorenzi, Enguerrane Martinez; Flem, François Xavier Le; André, N; Belleoud, Didier; Leparc-Goffart, Isabelle; Rousset, Dominique; Simon, Fabrice; Briolant, Sébastien

doi:10.1016/j.jcv.2018.09.015

Cited by 11 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Across studies, 56 (21.2%) of 264 individuals were found to have some degree of HL. 18,[22][23][24][25][26][27][28][29][30][31][32][33][34] Four of the fourteen articles described acquired HL in adults following Zika infection ( Table 1). The HL in these cases varied from moderate to severe and was reported as both unilateral and bilateral, with most patients experiencing recovery to normal or previous thresholds.…”

Section: Resultsmentioning

confidence: 99%

“…The HL in these cases varied from moderate to severe and was reported as both unilateral and bilateral, with most patients experiencing recovery to normal or previous thresholds. [22][23][24]30 Ten articles presented complication data of congenital Zika syndrome related to HL (Table 1). 18,22,[25][26][27][28][29][33][34][35] The majority of these studies used standard HL screening methods for infants, including measurement of auditory brainstem response and otoacoustic emission, which assesses cochlear function.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A Review of Hearing Loss Associated with Zika, Ebola, and Lassa Fever

Ficenec

Schieffelin

Emmett

2019

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

The neglected tropical diseases Zika, Ebola, and Lassa fever (LF) have all been noted to cause some degree of hearing loss (HL). Hearing loss is a chronic disability that can lead to a variety of detrimental effects, including speech and language delays in children, decreased economic productivity in adults, and accelerated cognitive decline in older adults. The objective of this review is to summarize what is known regarding HL secondary to these viruses. Literature for this review was gathered using the PubMed database. Articles were excluded if there were no data of the respective viruses, postinfectious complications, or conditions related to survivorship. A total of 50 articles were included in this review. Fourteen articles discussing Zika virus and subsequent complications were included. Across these studies, 56 (21.2%) of 264 Zika-infected individuals were found to have HL. Twenty-one articles discussing Ebola virus and subsequent complications were included, with 190 (5.7%) of 3,350 Ebola survivors found to have HL. Fifteen additional articles discussing LF and subsequent complications were included. Of 926 individuals with LF, 79 (8.5%) were found to have HL. These results demonstrate a relationship between HL and infection. The true prevalence is likely underestimated, however, because of lack of standardization of reporting and measurement. Future studies of viral sequelae would benefit from including audiometric evaluation. This information is critical to understanding pathophysiology, preventing future cases of this disability, and improving quality of life after survival of infection.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

A Review of Hearing Loss Associated with Zika, Ebola, and Lassa Fever

Ficenec

Schieffelin

Emmett

2019

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…Ethical approval of the ZIFAG cohort was given by the “Comité de Protection des Personnes Sud-Mediterranée” corresponding to the “Etude descriptive prospective de la maladie a virus Zika au sein de la communaute de defense des Forces Armees en Guyane—ZIFAG” and was registered on 29 February 2016 as RCB: 2016-A00394-47. Written consent was obtained from all participants [20].…”

Section: Methodsmentioning

confidence: 99%

“…A set of sera was selected (n = 242) from the 5,600 of the NRC Arbovirus serum bank, as well as a set from the ZIFAG cohort, and divided into four groups based on their genome detection, reaction against inactivated arboviruses, and epidemiological data (Table 1, SD1 Fig). The “ZIKV-RT-PCR-positive” group, from the ZIFAG one-year clinical follow-up cohort, is composed of 43 sera collected in French Guyana during the 2016 ZIKV outbreak [20, 21]. The ZIKV genome was detected by RT-PCR during the acute phase and tested sera were obtained during convalescence: 6 to 195 days post symptoms onset (DPSO).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

High specificity and sensitivity of Zika EDIII-based ELISA diagnosis highlighted by a large human reference panel

Denis¹,

Attoumani

Gravier

et al. 2019

PLoS Negl Trop Dis

Self Cite

View full text Add to dashboard Cite

BackgroundZika virus (ZIKV) and Dengue virus (DENV) are often co-endemic. The high protein-sequence homology of flaviviruses renders IgG induced by and directed against them highly cross-reactive against their antigen(s), as observed on a large set of sera, leading to poorly reliable sero-diagnosis.MethodsWe selected Domain III of the ZIKV Envelope (ZEDIII) sequence, which is virus specific. This recombinant domain was expressed and purified for the specific detection of ZEDIII-induced IgG by ELISA from ZIKV-RT-PCR-positive, ZIKV-IgM-positive, flavivirus-positive but ZIKV-negative, or flavivirus-negative sera. We also assessed the reactivity of ZEDIII-specific human antibodies against EDIII of DENV serotype 4 (D4EDIII) as a specific control. Sera from ZEDIII-immunized mice were also tested.ResultsCross-reactivity of IgG from 5,600 sera against total inactivated DENV or ZIKV was high (71.0% [69.1; 72.2]), whereas the specificity and sensitivity calculated using a representative cohort (242 sera) reached 90% [84.0; 95.8] and 92% [84.5; 99.5], respectively, using a ZEDIII-based ELISA. Moreover, purified human IgG against D2EDIII or D4EDIII did not bind to ZEDIII and we observed no D4EDIII reactivity with ZIKV-induced mouse polyclonal IgGs.ConclusionsWe developed a ZEDIII-based ELISA that can discriminate between past or current DENV and ZIKV infections, allowing the detection of a serological scar from other flaviviruses. This could be used to confirm exposure of pregnant women or to follow the spread of an endemic disease.

show abstract

Prevalence and characteristics of new‐onset pain in COVID‐19 survivours, a controlled study

Soares

Kubota

Fernandes

et al. 2021

European Journal of Pain

View full text Add to dashboard Cite

We assessed whether COVID‐19 is associated with de novo pain and de novo chronic pain (CP). This controlled cross‐sectional study was based on phone interviews of patients discharged from hospital after COVID‐19 compared to control group composed of individuals hospitalized during the same period due to non‐COVID‐19 causes. Patients were classifyed as having previous CP based on the ICD‐11/IASP criteria, de novo pain (i.e., any new type of pain, irrespective of the pain status before hospital stay), and de novo CP (i.e. persistent or recurring de novo pain, lasting more than 3 months) after COVID‐19. We asssessed pain prevalence and its characteristics, including headache profile, pain location, intensity, interference, and its relationship with fatigue, and persistent anosmia. Forty‐six COVID‐19 and 73 control patients were included. Both groups had similar sociodemographic characteristics and past medical history. Length of in‐hospital‐stay and ICU admission rates were significantly higher among COVID‐19 survivors, while mechanical ventilation requirement was similar between groups. Pre‐hospitalization pain was lower in COVID‐19 compared to control group (10.9% vs. 42.5%; P=0.001). However, COVID‐19 group had a significantly higher prevalence of de novo pain (65.2% vs. 11.0%, P=0.001), as well as more de novo headache (39.1%) compared to controls (2.7%, p=0.001). New‐onset CP was 19.6% in COVID‐19 patients and 1.4% (P=0.002) in controls. These differences remained significant (p=0.001) even after analyzing exclusively (COVID: n=40; controls: n=34) patients who did not report previous pain before hospital stay. No statistically significant differences were found for mean new‐onset pain intensity and interference with daily activities between both groups. COVID‐19 pain was more frequently located in the head/neck and lower limbs (P<0.05). New‐onset fatigue was more common in COVID‐19 survivors necessitating inpatient hospital care (66.8%) compared to controls (2.5%, p=0.001). COVID‐19 patients who reported anosmia had more new‐onset pain (83.3%) compared to those who did not (48.0%, P=0.024). COVID‐19 was associated with a significantly higher prevalence of de novo CP, chronic daily headache, and new‐onset pain in general, which was associated with persistent anosmia.

show abstract

Evolution of symptoms and quality of life during Zika virus infection: A 1-year prospective cohort study

Cited by 11 publications

References 28 publications

A Review of Hearing Loss Associated with Zika, Ebola, and Lassa Fever

A Review of Hearing Loss Associated with Zika, Ebola, and Lassa Fever

High specificity and sensitivity of Zika EDIII-based ELISA diagnosis highlighted by a large human reference panel

Prevalence and characteristics of new‐onset pain in COVID‐19 survivours, a controlled study

Contact Info

Product

Resources

About